Table 1.

Patient characteristics

Clinical CharacteristicActive Rejection GroupNo Active Rejection GroupP Valuea
Number of patients2775
Number of samples2780
Race, n (%)0.23
 Black13 (48)23 (31)
 White13 (48)41 (55)
 Native Hawaiian or Other Pacific Islander1 (4)0 (0)
 Hispanic/Latino0 (0)4 (5)
 Asian0 (0)1 (1)
 Other0 (0)6 (8)
Men, n (%)16 (59)45 (60)>0.99
Age at enrollment, y46±1653±130.04
Post-transplant, d968±11071189±14820.42
CMV serologic status, n (%)0.15
 D−/R+4 (15)13 (17)
 D+/R+5 (19)24 (32)
 D−/R−3 (11)16 (21)
 D+/R−4 (15)9 (12)
 Unknown11 (41)13 (17)
Donor type, n (%)0.03
 Deceased donor20 (74)42 (56)
 Living unrelated2 (7)24 (32)
 Living related5 (19)9 (12)
 Child2 (7)3 (4)
 Sibling2 (7)4 (5)
 Parent0 (0)1 (1)
 Half-sibling0 (0)0 (0)
 Other biologic blood relation1 (4)1 (1)
Creatinine2.5±1.02.4±1.40.69
eGFR32±1236±210.21
HLA class 1 no. of mismatches (A, B)2.7±1.42.6±1.40.59
HLA class 2 no. of mismatches (DR)1.2±0.61.1±0.80.67
Weight, kg85±1984±210.73
Height, cm170±10171±80.58
  • Data ranges are presented as mean±standard deviation. CMV, cytomegalovirus.

  • a The P values are the level of statistical significance in the differences of values found in the DART active rejection group and the no active rejection group. For continuous covariates, Wilcoxon rank sum test was used to generate the P values. For categoric covariates, Fisher exact test was used to generate the P values.